Page last updated: 2024-08-23

mefloquine and gdc-0973

mefloquine has been researched along with gdc-0973 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Borison, J; Collisson, EA; Courau, T; Jiang, H; Krummel, MF; Mayer, AT; Ritchie, AJ	1

Other Studies

1 other study(ies) available for mefloquine and gdc-0973

Article	Year
Activating Immune Recognition in Pancreatic Ductal Adenocarcinoma via Autophagy Inhibition, MEK Blockade, and CD40 Agonism. Gastroenterology, 2022, Volume: 162, Issue:2 Topics: Animals; Autophagy; Azetidines; Carcinoma, Pancreatic Ductal; CD40 Antigens; Cell Line, Tumor; Drug Synergism; Humans; Hydroxychloroquine; Immunotherapy; Interferon Type I; Macrophages; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mefloquine; Membrane Proteins; Mice; Pancreatic Neoplasms; Paracrine Communication; Piperidines; Protein Kinase Inhibitors; Tumor Escape; Tumor Microenvironment; Tumor-Associated Macrophages	2022

Article

Year

Activating Immune Recognition in Pancreatic Ductal Adenocarcinoma via Autophagy Inhibition, MEK Blockade, and CD40 Agonism.

Gastroenterology, 2022, Volume: 162, Issue:2

Topics: Animals; Autophagy; Azetidines; Carcinoma, Pancreatic Ductal; CD40 Antigens; Cell Line, Tumor; Drug Synergism; Humans; Hydroxychloroquine; Immunotherapy; Interferon Type I; Macrophages; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mefloquine; Membrane Proteins; Mice; Pancreatic Neoplasms; Paracrine Communication; Piperidines; Protein Kinase Inhibitors; Tumor Escape; Tumor Microenvironment; Tumor-Associated Macrophages

2022